Tumorigenesis role and clinical significance of DJ-1, a negative regulator of PTEN, in supraglottic squamous cell carcinoma by Xiao-Lin Zhu et al.
Zhu et al. Journal of Experimental & Clinical Cancer Research 2012, 31:94
http://www.jeccr.com/content/31/1/94RESEARCH Open AccessTumorigenesis role and clinical significance of
DJ-1, a negative regulator of PTEN, in supraglottic
squamous cell carcinoma
Xiao-Lin Zhu1,2, Zhang-Feng Wang1,2, Wen-Bin Lei1,2, Hui-Wen Zhuang1,2, Wei-Jian Hou1,2, Yi-Hui Wen1,2
and Wei-Ping Wen1,2*Abstract
Background: DJ-1 can induce the tumor cell proliferation and invasion via down-regulating PTEN in many
malignant tumors, and correlated to prognostic significance. However, the tumorigenesis role and clinical
significance of DJ-1 in supraglottic squamous cell carcinoma (SSCC) is unclear. We aimed to evaluate the DJ-1 the
relationship between DJ-1 and clinicopathological data including patient survival.
Methods: The expression of DJ-1 and PTEN in SSCCs (52) and adjacent non-cancerous tissues (42) was assessed by
immunohistochemistry (IHC), and the relationship between DJ-1 and clinicopathological data was analyzed.
Results: DJ-1 was detected mainly in SSCCs (88.5%) and less frequently in adjacent non-cancerous tissues (21.0%).
PTEN expression was detected in 46.2% of SSCCs and in 90.5% of adjacent non-cancerous tissues. DJ-1 expression
was linked to nodal status (P = 0.009), a highly significant association of DJ-1 expression with shortened patient
overall survival (5-year survival rate 88.0% versus 53.9%; P = 0.007; log rank test) was demonstrated.
Conclusions: Our data suggested that DJ-1 over-expression was linked to nodal status, and might be an
independent prognostic marker for patients with SSCC.
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Laryngeal squamous cell carcinoma (LSCC), one of the
most common malignancies of the head and neck region,
accounts for approximately 2.4% of new malignancies
worldwide every year [1,2]. Supraglottic squamous cell
carcinoma (SSCC), one advanced type of LSCC, is often
accompanied by lymph node metastasis or even systemic
metastasis, and usually results in substantial annual mor-
bidity and mortality. Hence, to predict the biology of the
tumor and the course of the disease in individual patient
is importance for appropriate therapy and patient surveil-
lance. The evaluation of a SSCC patient’s prognosis and
predictive markers is primarily based on the clinical tumor-* Correspondence: wwp1901@yahoo.com.cn
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reproduction in any medium, provided the ornode-metastasis (TNM) staging [3]. However, patients with
SSCC with similar clinical stage classifications usually have
different clinical outcomes, suggesting that TNM sta-
ging is not sufficient for precisely determining a SSCC
prognosis. Therefore, identifying specific biomarkers
which have diagnostic and prognostic value for SSCC
remains a priority.
DJ-1, a mitogendependent oncogene, was firstly reported
by Nagakubo in 1997 [4]. Recent studies indicated that DJ-1
is closely related to the proliferation, metastasis, occurrence,
and prognosis of the malignant tumors [2,5-13]. In our
recent study of glottic squamous cell carcinoma [2], DJ-1
was shown as an independent molecular marker for poor
prognosis, and was correlated with pT status and tumor
grading. In other LSCC studies [2], DJ-1was also identified
as an activator of cell proliferation, and was related to T
stage and poor prognosis [14,15]. However, the relation-
ship between DJ-1 and lymph node metastasis of LSCC
have not been revealed both in our and others’ studies.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathological parameters of the tumor set
Number of cases %
Gender Male 49 94.2
Female 3 5.8
Age(y) ≤ 61 25 48.1
> 61 27 51.9






pN status N0 24 46.2
N1 16 30.7
N2 12 23.1






Tumor grade G1 17 32.6
G2 21 40.5
G3 14 26.9
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specific phosphatase that plays an important role in
tumorigenesis and reduced PTEN expression is associated
with cell survival, proliferation, tumor invasion, and tumor-
node-metastasis (TNM) stage [14-20]. Furthermore, LSCC
studies showed that reduced PTEN expression is also
related to cell proliferation, tumor invasion, lymphatic
metastasis, and TNM stage [21-23]. Recent studies have
showed that PTEN might be regulated by DJ-1 in several
cancers, such as renal cell carcinoma, breast cancer, blad-
der carcinoma, and ovarian carcinoma [8,24-26]. Kim RH
[8] found that DJ-1 could activate cell proliferation and
transformation by negatively regulating PTEN expression
in breast cancer cells. The above evidence suggests
that the DJ-1-induced PTEN down-regulation may be
involved in LSCC progression and act as activator of
the invasion process in LSCC.
To date, the relationship between DJ-1 and clinico-
pathological data including patient survival in SSCC
have not been revealed. The aim of this study was to in-
vestigate the relationship between DJ-1 and clinico-
pathological data including patient survival.
Material and methods
Patients
A total of fifty seven SSCC patients were eligible for this
study. 2 and 3 patients were excluded because of insuffi-
cient tissue samples and incomplete follow-up data, re-
spectively. 52 subjects with SSCCs and 42 subjects with
adjacent non-cancerous tissues were thus examined.
These patients underwent surgery in our department from
January 1996 to September 2006, and clinical follow-up
data were completed. The average observation time for
overall survival was 62 months for patients still alive at
the time of analysis, and ranged from 7 to 122 months.
Twenty-eight patients (53.8%) died during follow-up.
Tumor tissues from the resected specimens and adjacent
non-cancerous tissues were used as normal control (tumor
and adjacent non-cancerous tissues were confirmed by
pathologic examination). The tissues used for immunohis-
tochemistry were fixed in 4% polyformaldehyde and
embedded in paraffin. All specimens and clinical data
in this study were procured, handled, and maintained
according to the protocols approved by Institutional
Review Board (IRB), and all of the patients who partici-
pated in the study provided informed consent.
The principal inclusion criteria were primary squamous
cell carcinoma of the supraglottis type only, no history of
previous malignant disease, and no history of previous
radio- or chemotherapy. The main clinical and pathologic
characteristics of the patients are presented in Table 1: 49
(94.2%) were male and with a median age was 59.0 years
(ranging from 39–81 years of age). Clinical staging and
the anatomic site of the tumors were assessed accordingto the 6th edition of the Union Internationale Contre
Cancer (UICC) tumor-node-metastasis classification of
malignant tumors.
Immunohistochemical staining
Immunohistochemistry staining was carried out as previ-
ously described [2]. DJ-1 polyclonal antibody (Santa
Cruz Biotechnology, Santa Cruz, California, USA) and
PTEN monoclonal antibody (Cell Signaling Technology,
Denver). DJ-1 staining was graded according to the in-
tensity and extent of staining of the epithelium as previ-
ously described, and immunostaining of all slides were
evaluated in a blinded manner [2].
Fluorescent immunohistochemistry
To better confirm the cellular location and the relation-
ship between DJ-1 and PTEN in SSCC tissues, fluores-
cent immunohistochemistry was performed as described
previously [27].
Statistical analysis
Statistical analysis was performed with the SPSS software
(SPSS Standard version 13.0, SPSS). The association of
DJ-1 protein expression with SSCC patient’s clinico-
pathological features and the recorrelation between
Figure 1 Expression of DJ-1 in SSCC clinical samples and univariate survival analysis. A. DJ-1 staining showed low expression of DJ-1 in
adjacent non-cancerous tissues, and high expression of DJ-1 was found in cytoplasm of SSCC tumor tissues (IHC, 400X). In comparison, PTEN
staining of adjacent non-cancerous tissues was stronger and more common than that of SSCCs (IHC, 400X). B. Fluorescent-IHC clearly
demonstrates that strong expression of DJ-1 is found in cytoplasm of SSCC tumor cells, while poor staining of PTEN was observed in cytoplasm
of SSCC tumor cells, and that strong expression of PTEN is found in cytoplasm of adjacent non-cancerous cells, while poor staining of DJ-1 was
observed in cytoplasm of adjacent non-cancerous cells (IHC, 400X). C. Kaplan-Meier curves with univariate analyses (log-rank) comparing tumors
with low- grade DJ-1 expression with those with high-grade DJ-1 expression. Patients with low-grade DJ1 expression had a cumulative 5-year
survival rate of 88.0% compared with 53.9% for patients with high-grade DJ-1 expression.
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Table 2 DJ-1 and PTEN expression in adjacent non-cancerous tissues and SSCCs
DJ-1 expression, n (%) PTEN expression, n (%) Total
Absent Low High Absent Low High
SSCC 6 (11.5%) 12 (23.1%) 34 (65.4%) 28 (53.8%) 16 (30.8%) 8 (15.4%) 52
Normal 22 (52.4) 11 (26.2%) 9 (21.4%) 4 (9.5%) 10 (23.8%) 28 (66.7%) 42
DJ-1: χ2 = 22.917; df = 2; P = 0.000. SSCC, supraglottic squamous cell carcinoma.
PTEN: χ2 = 29.769; df = 2; P = 0.000.
Table 3 Relationship between DJ-1 expression and
various clinicopathological factors
Characteristic All cases DJ-1 DJ-1 P
Low-grade High-grade
All carcinomas 52 18 34
Age 1.000
≤ 61 25 9 16
> 61 27 9 18
pT status 0.003
Tis-2 15 10 5
T3-4 37 8 29
pN status 0.009
N0 24 13 11
N1-3 28 5 23
UICC stage 0.022
0-II 10 7 3
III-IV 42 11 31
Histological grade 0.758
G1 17 5 12
G2-3 35 13 22
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χ2 test or Fischer’s exact test. For survival analysis, we
analyzed all SSCC patients by Kaplan-Meier analysis. Log-
rank test was used to compare different survival curves.
Multivariate survival analysis was performed on all para-
meters the Cox regression model. P < 0.05 was considered
to be statistically significant.
Results
DJ-1 and PTEN expression in SSCCs and adjacent non-
cancerous tissues
DJ-1 was detected mainly in SSCCs and less frequently
in adjacent non-cancerous tissues. In comparison, PTEN
staining of adjacent non-cancerous tissues was stronger
and more common than that of SSCCs (Figure 1A). To
better study the cellular location and the relationship be-
tween DJ-1 and PTEN in SSCCs, fluorescent immuno-
histochemistry was performed, and the results showed
that strong expression of DJ-1 is found in cytoplasm of
SSCC tumor cells, while poor staining of PTEN was
observed in cytoplasm of SSCC tumor cells, and that
strong expression of PTEN is found in cytoplasm of ad-
jacent non-cancerous cells, while poor staining of DJ-1
was observed in cytoplasm of adjacent non-cancerous
cells (Figure 1B). A summary of DJ-1 and PTEN expres-
sion in normal and SSCC tissues is given in Table 2. DJ-1
expression was detected in 88.5% of SSCCs and in 21.0%
of adjacent non-cancerous tissues examined, whereas
PTEN expression was detected in 46.2% of SSCCs and in
90.5% of adjacent non-cancerous tissues. Moreover, 65.4%
of SSCCs were assessed as high grade DJ-1 staining,
whereas 78.6% of adjacent non-cancerous tissue had either
no or low-grade DJ-1 staining. A significant difference in
grade of DJ-1 expression was demonstrated between
SSCCs and adjacent non-cancerous tissues (P < 0.001).
Further more, we find that DJ-1 expression was linked to
lymph nodal status (P = 0.042), pT status (P = 0.037), and
UICC stage (P = 0.027), and there was no significant asso-
ciation of overall DJ-1 staining intensity with patient age
and tumor grading (Table 3).
DJ-1 is a prognostic marker for SSCC
In univariate survival analysis, cumulative survival
curves were calculated according to the Kaplan-Meier
method (Table 4). Differences in survival were assessed
with the long-rank test. The conventional prognosticparameters pT status, lymph node status, and disease
stage according to UICC reached significance for overall
survival. DJ-1 positivity was associated with overall sur-
vival (P = 0.007). Figure 1C illustrates the impact of DJ-1
expression on survival times.
The multivariate analysis was based on the Cox regres-
sion model to test the influence of each parameter on
overall survival. We tested the impact of DJ-1 expression
on overall survival. The results showed that the overall
survival time was significantly dependent on DJ-1
expression, pT status, and UICC stage.
Discussion
The current TNM staging and histopathological grading
systems are useful prognostic indicators for SSCC [3]. How-
ever, they have limitations with regard to providing critical
information regarding patient prognosis. Patients with the
same clinical stage and/or pathological grade of SSCC often
display considerable variability in disease recurrence and
survival [1,28]. Therefore, new objective measures and bio-
markers are necessary to effectively differentiating patients
with favorable outcomes from those with less favorable
Table 4 Univariate survival analyses (Kaplan-Meier):
survival time of all patients with SSCC according to







Rate ( ± SE)
P
DJ-1 expression 0.007
Low-grade 18 7 88.0 ± 8.0
High-grade 34 21 53.9 ± 5.7
Age 0.244
≤61 25 11 72.2 ± 7.9
> 61 27 17 58.5 ± 7.0
pT status 0.037
Tis-2 15 5 87.0 ± 10.3
T3-4 37 23 57.5 ± 5.5
pN status 0.042
N0 24 12 76.0 ± 7.7
N1-3 28 16 52.8 ± 5.6
UICC stage 0.027
0-II 10 3 99.5 ± 8.4
III-IV 42 25 58.5 ± 5.4
Histological grade 0.597
G1 17 9 68.9 ± 9.4
G2-3 35 19 62.8 ± 6.4
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standard TNM and histopathological strategies have the po-
tential to predict prognoses more effectively.
DJ-1 protein is coded by exons 27, contains 189 amino
acids, and weights about 20 kD, and was firstly defined
as an oncogene candidate in 1997 [4]. Recent studies
showed that DJ-1 is expressed highly in many types of
human malignancies [2,5-15]. Lines of evidence have
also suggested that the over-expression of DJ-1 is corre-
lated with more aggressive clinical behaviors of pancre-
atic, esophageal and lung cancers [10-13]. However, in
our recent glottic squamous cell carcinoma study [2],
DJ-1 has only been identified as a prognostic marker
and activator of cell proliferation, and the expression of
DJ-1 was not correlated to clinical lymph node metasta-
sis. This non-invasive role of DJ-1 in glottic squamous
cell carcinoma which is contradictory to the invasive role
of DJ-1 in other malignancies may be attributed to the
clinical and biological behavior of glottic squamous cell
carcinoma, as this type of LSCC was poorly invaded in
clinic. So, in order to identify whether DJ-1 also play the
invasive role in LSCC, SSCC, the more aggressive type
of LSCC, was selected in the present study.
Recently, several studies showed that PTEN in human
malignancies is associated with cell proliferation, tumor
invasion, and TNM stage, and can be down-regulatedby DJ-1 in several cancers, such as renal cancer, breast
cancer, bladder cancer, and ovarian cancer [8,24-26]. In
2005, Kim RH [8] found that DJ-1 could activate cell
proliferation and transformation by negatively regulating
PTEN expression in breast cancer cells. In 2012, Lee H
[25] showed that over-expression of DJ-1 and loss of
PTEN are associated with invasive urothelial carcinoma
of urinary bladder. Taken together, we hypothesized
that DJ-1 would promote migration and invasion of SSCC
via down-regulating the expression of PTEN, and may
associated with clinical lymph node status in SSCC.
In the immunohistochemistry-based study, we exam-
ined the expression of both DJ-1 and PTEN in SSCC
tissue versus adjacent non-cancerous tissue. Our results
indicate that the expression of DJ-1 was mainly in SSCCs
and less frequently in adjacent non-cancerous tissues,
whereas PTEN staining of adjacent non-cancerous tissues
was stronger and more common than that of SSCCs
(Figure 1A, B). Furthermore, an significant difference in
grade of DJ-1 expression was demonstrated between
SSCCs and adjacent non-cancerous tissues (P < 0.001),
and pT status (P = 0.003) and nodal status (P = 0.009) were
linked to DJ-1 expression. This scenario is similar to that
observed in other type of human cancers [5-13], and the
relationship between nodal status and DJ-1 expression in
SSCC revealed that DJ-1 may play an invasive role in
SSCC. In both univariate and multivariate survival ana-
lysis, our study suggests that DJ-1, a prognostic marker for
GSCC in our previous study [2], is also a prognostic mar-
ker in SSCC (Figure 1C). Thus, expression of DJ-1 appears
to have the potential to predict SSCC patients’ outcome.
Conclusions
In conclusion, to the authors’ knowledge, the current
study is the first to demonstrate the relationship be-
tween DJ-1 and clinicopathological data including lymph
node status in SSCC. Furthermore, survival analysis
showed that DJ-1 is an independent prognostic maker
for reduced patient survival in SSCC. Collectively, the
present findings would provide important information
into the future design of individualized therapeutic strat-
egies for SSCC with different DJ-1 expression levels.
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